INS and diabetes mellitus: Although these agents are associated with a lower risk of hypoglycemia compared to other diabetes medications such as sulfonylureas or insulin [2], hypoglycemia remains a reported side effect—even in clinical trials involving patients with obesity and no underlying diabetes [3, 4].